RecruitingPhase 3

A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Argentina, Australia190 participantsStarted 2019-04-05

Plain-language summary

The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.

Who can participate

Age range1 Year – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participants must have completed a previous study of baricitinib for the treatment of JIA. Exclusion Criteria: * Participants must not have had a permanent discontinuation of baricitinib in the prior study. * Participants must have not developed an allergy to baricitinib.

What they're measuring

Number of Participants with One or More Serious Adverse Event(s) (SAEs)

Timeframe: Baseline through Week 264

Number of Participants with Permanent Investigational Product Discontinuations

Timeframe: Baseline through Week 264

Trial details

NCT IDNCT03773965

SponsorEli Lilly and Company

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2031-07

Contact for this trial

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

1-317-615-4559 LillyTrials@Lilly.com

View on ClinicalTrials.gov More Juvenile Idiopathic Arthritis trials